Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis president joins Qu Biologics

Robert Pelzer is appointed board member at immunotherapy specialists

Qu Biologics Robert Pelzer

Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.

Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.

He was previously global general counsel and head of legal services for Novartis at a corporate level.

Before joining Novartis in 2002, he spent several years at DuPont Pharmaceuticals, serving as general counsel and senior VP.

His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease.

“Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development,” said CEO of Qu Biologics Dr Hal Gunn, who also noted that Pelzer will help develop relationships with potential pharma partners.

18th June 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...